par Pugliano, Lina 
;Zardavas, Dimitros ;Piccart-Gebhart, Martine
Référence Magazine of European Medical Oncology, 6, 3, page (158-166)
Publication Publié, 2013-09
;Zardavas, Dimitros ;Piccart-Gebhart, Martine Référence Magazine of European Medical Oncology, 6, 3, page (158-166)
Publication Publié, 2013-09
Article révisé par les pairs
| Résumé : | The National Cancer Institute of the United States defines personalized medicine (PM) as a form of medicine that uses information about a person's genes, proteins and environment to prevent, diagnose and treat disease (National Cancer Institute, Dictionary of Cancer Terms) [1]. Consequently, the ultimate dream is the generation of a molecular fingerprint via a simple blood test or tumor sample that allows the physician to refine an individual patient's prognosis, select the best possible therapeutic option, and minimize the toxicity from therapies by identification of distinct genetic markers. The enormous gains to patients and ultimately health care systems are unmistakable. © Springer-Verlag Wien 2013. |
